Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study: A Phase I Randomized, Controlled, Dose-Escalation Study

OBJECTIVE: To evaluate the safety and tolerability of multiple intravenous (IV) doses of sifalimumab in adults with moderate-to-severe systemic lupus erythematosus (SLE). METHODS: In this multicenter, double-blind, placebo-controlled, sequential dose-escalation study, patients were randomized 3:1 to...

Descripción completa

Detalles Bibliográficos
Autores principales: Petri, Michelle, Wallace, Daniel J, Spindler, Alberto, Chindalore, Vishala, Kalunian, Kenneth, Mysler, Eduardo, Neuwelt, C Michael, Robbie, Gabriel, White, Wendy I, Higgs, Brandon W, Yao, Yihong, Wang, Liangwei, Ethgen, Dominique, Greth, Warren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Subscription Services, Inc., A Wiley Company 2013
Materias:
Systemic Lupus Erythematosus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654174/
https://www.ncbi.nlm.nih.gov/pubmed/23400715
http://dx.doi.org/10.1002/art.37824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654174/
https://www.ncbi.nlm.nih.gov/pubmed/23400715
http://dx.doi.org/10.1002/art.37824

Ejemplares similares